An Analysis of Bevacizumab or Cetuximab for CRC


Tanios Bekaii-Saab, MD
Published Online: Aug 13, 2014

Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).

Read more about the treatment of CRC > >

$vAR$